Kublickiene K R, Wolff K, Kublickas M, Lindblom B, Lunell N O, Nisell H
Department of Obstetrics and Gynecology, Karolinska Institute, Huddinge University Hospital, Sweden.
Am J Hypertens. 1994 Jul;7(7 Pt 2):50S-55S. doi: 10.1093/ajh/7.7.50s.
The results of our previous studies suggested that endothelin-1 (ET-1) might be contributory to the impaired uteroplacental blood flow seen in preeclampsia. The aim of this study was to investigate the in vitro influence of isradipine on ET-1-induced contraction of myometrial resistance arteries from pregnant women, as these vessels are partly responsible for the regulation of uteroplacental blood flow in preeclampsia. Small myometrial arteries were dissected from myometrium obtained from 20 normotensive term pregnant women undergoing elective cesarean section and mounted in a tissue chamber. Tension was recorded isometrically. When ET-1 (10(-8) mol/L)-contracted vessels were exposed to increasing concentrations (10(-6), 10(-5), and 10(-4) mol/L) of isradipine, the myometrial arteries demonstrated essentially no relaxation. A significant mean relaxation of 31% was seen only with the highest isradipine concentration of 10(-3) mol/L. Pretreatment with isradipine attenuated ET-1-induced contraction by 26% at 3 x 10(-4) mol/L and by up to 80% at 10(-3) mol/L. Preincubation with lower concentrations of isradipine did not significantly reduce subsequent ET-1 contraction. The present study has thus shown that isradipine at high concentrations counteracts ET-1-induced constriction of myometrial arteries in term pregnant women. Pretreatment with isradipine at high concentrations attenuates the ET-1 contraction.
我们之前的研究结果表明,内皮素 -1(ET-1)可能与子痫前期所见的子宫胎盘血流受损有关。本研究的目的是调查异搏定对ET-1诱导的孕妇子宫肌层阻力动脉收缩的体外影响,因为这些血管在子痫前期子宫胎盘血流调节中起部分作用。从20名接受择期剖宫产的血压正常的足月孕妇的子宫肌层中分离出小的子宫肌层动脉,并安装在组织浴槽中。等长记录张力。当ET-1(10^(-8)mol/L)收缩的血管暴露于递增浓度(10^(-6)、10^(-5)和10^(-4)mol/L)的异搏定时,子宫肌层动脉基本没有舒张。仅在异搏定最高浓度10^(-3)mol/L时才观察到31%的显著平均舒张。在3×10^(-4)mol/L时,异搏定预处理使ET-1诱导的收缩减弱26%,在10^(-3)mol/L时减弱高达80%。用较低浓度的异搏定预孵育并未显著降低随后的ET-1收缩。因此,本研究表明,高浓度的异搏定可对抗ET-1诱导的足月孕妇子宫肌层动脉收缩。高浓度异搏定预处理可减弱ET-1收缩。